Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

101. Erratum to 'Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs' [Musculoskeletal. Ther. and Pract. 29C (2017) 66-71]. (PubMed)

Erratum to 'Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs' [Musculoskeletal. Ther. and Pract. 29C (2017) 66-71]. 28628805 2018 06 05 2468-7812 31 2017 10 Musculoskeletal science & practice Musculoskelet Sci Pract Erratum to 'Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs' [Musculoskeletal. Ther. and Pract. 29C (2017) 66-71]. 21

2017 Musculoskeletal science & practice

102. Effect of Transfusion on Mortality and Other Adverse Events Among Critically Ill Septic Patients: An Observational Study Using a Marginal Structural Cox Model

Effect of Transfusion on Mortality and Other Adverse Events Among Critically Ill Septic Patients: An Observational Study Using a Marginal Structural Cox Model RBC transfusion is often required in patients with sepsis. However, adverse events have been associated with RBC transfusion, raising safety concerns. A randomized controlled trial validated the 7 g/dL threshold, but previously transfused patients were excluded. Cohort studies led to conflicting results and did not handle time-dependent

2017 EvidenceUpdates

103. Tumor- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. (Full text)

Tumor- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1) produce unique toxicity profiles. The objective of this review was to identify patterns and incidence of immune-related adverse events (irAE) based on tumour type and ICI class.Medline, EMBASE

2017 Annals of oncology : official journal of the European Society for Medical Oncology PubMed

104. Postmarketing Adverse Events Related to the CardioMEMS HF System (Full text)

Postmarketing Adverse Events Related to the CardioMEMS HF System 28975249 2018 11 13 2380-6591 2 11 2017 Nov 01 JAMA cardiology JAMA Cardiol Postmarketing Adverse Events Related to the CardioMEMS HF System. 1277-1279 10.1001/jamacardio.2017.3791 Vaduganathan Muthiah M Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. DeFilippis Ersilia M EM Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts

2017 JAMA cardiology PubMed

105. Association of Guideline Adherence for Serial Evaluations With Survival and Adverse Clinical Events in Patients With Asymptomatic Severe Aortic Stenosis (Full text)

Association of Guideline Adherence for Serial Evaluations With Survival and Adverse Clinical Events in Patients With Asymptomatic Severe Aortic Stenosis For patients with asymptomatic severe aortic stenosis and normal left ventricular function, current practice guidelines empirically recommend serial evaluations every 6 to 12 months. The benefit of this clinical monitoring is unknown.To determine the association of guideline adherence with clinical outcomes in patients with asymptomatic severe (...) aortic stenosis.This retrospective cohort study involved 300 patients with asymptomatic severe aortic stenosis who were seen in the ambulatory Minneapolis Heart Institute at Abbott Northwestern Hospital. Rates of survival and adverse clinical events, including myocardial infarction, stroke, and heart failure hospitalization, were compared between patients who adhered to serial evaluation guidance and those who did not. Medical records were reviewed from July 25, 2007, to December 6, 2012. Data

2017 JAMA cardiology PubMed

106. Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging and Major Adverse Coronary Events

Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging and Major Adverse Coronary Events "Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging and " by Kolten Paryzek and Chase Beal < > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Coronary artery disease is the most common type of heart disease. CAD encompasses atherosclerosis (...) of care currently involves the use electrocardiogram (ECG), computed tomography (CT), and echocardiogram in order to monitor cardiac function. A new emerging imaging study, cardiac magnetic resonance with late gadolinium enhancement, has shown to be a promising prognostic tool in evaluating patient’s risks for major adverse coronary events (MACE). CMR is a medical imaging technology for non-invasive assessment for the function and structure of the heart. Gadolinium is a contrast agent that can

2017 Pacific University EBM Capstone Project

107. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events (Full text)

Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events Sulfonylureas have been associated with an increased risk of cardiovascular adverse events and hypoglycemia, but it is unclear if these risks vary with different agents. We assessed whether the risks of acute myocardial infarction, ischemic stroke, cardiovascular death, all-cause mortality, and severe hypoglycemia differ between sulfonylureas grouped according to pancreas specificity (...) -1.003), but with an increased risk of severe hypoglycemia (HR 2.83; CI 1.64-4.88).The nonspecific, long-acting sulfonylureas glyburide and glimepiride do not have an increased risk of cardiovascular adverse events compared with the specific, short-acting sulfonylureas gliclazide, glipizide, and tolbutamide. However, nonspecific, long-acting sulfonylureas glyburide and glimepiride have an increased risk of severe hypoglycemia.© 2017 by the American Diabetes Association.

2017 EvidenceUpdates PubMed

108. Differences in Adverse Drug Events Among Pediatric Patients With and Without Cancer: Sub-Analysis of a Retrospective Cohort Study (Full text)

Differences in Adverse Drug Events Among Pediatric Patients With and Without Cancer: Sub-Analysis of a Retrospective Cohort Study This study investigated the differences in the incidence and severity of adverse drug events (ADEs) in pediatric patients with and without cancer.We used data from the Japan Adverse Drug Events Study for pediatrics, a cohort study enrolling pediatric inpatients at two tertiary care teaching hospitals in Japan. ADEs were identified by on-site review of all medical

2017 Drugs - real world outcomes PubMed

109. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events

Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative cardiovascular and cerebrovascular safety of adding a second long-acting bronchodilator in patients with COPD.We identified a cohort of COPD patients, new users of LABA or the LAMA tiotropium during 2002-2012, from the UK Clinical Practice (...) , was not associated with an increased risk of AMI (hazard ratio (HR) 1.12, 95% CI 0.92-1.36), stroke (HR 0.87, 95% CI 0.69-1.10) or arrhythmia (HR 1.05, 95% CI 0.81-1.36), but the risk was elevated for heart failure (HR 1.16, 95% CI 1.03-1.30).Adding a second long-acting bronchodilator in the real-world-setting treatment of COPD does not increase the risk of most cardiovascular events. The modest increase for heart failure warrants further investigation.Copyright ©ERS 2017.

2017 EvidenceUpdates

110. Adverse Events With Ketamine Versus Ketofol for Procedural Sedation on Adults: A Double-blind, Randomized Controlled Trial (Full text)

Adverse Events With Ketamine Versus Ketofol for Procedural Sedation on Adults: A Double-blind, Randomized Controlled Trial The goal of our study was to compare the frequency and severity of recovery reactions between ketamine and ketamine-propofol 1:1 admixture ("ketofol").We performed a multicentric, randomized, double-blind trial in which adult patients received emergency procedural sedations with ketamine or ketofol. Our primary outcome was the proportion of unpleasant recovery reactions (...) . Other outcomes were frequency of interventions required by these recovery reactions, rates of respiratory or hemodynamic events, emesis, and satisfaction of patients as well as providers.A total of 152 patients completed the study, 76 in each arm. Compared with ketamine, ketofol determined a 22% reduction in recovery reactions incidence (p < 0.01) and less clinical and pharmacologic interventions required by these reactions. There was no serious adverse event in both groups. Rates in hemodynamic

2017 EvidenceUpdates PubMed

111. Relationship Between Adverse Tracheal Intubation Associated Events and PICU Outcomes

Relationship Between Adverse Tracheal Intubation Associated Events and PICU Outcomes PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2017 PedsCCM Evidence-Based Journal Club

112. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). (Full text)

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we (...) until disease progression, unacceptable toxic effects, voluntary withdrawal by the patient, or complete response. We stratified randomisation by GOG performance status (0 vs 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic). We gave treatment open label. Primary outcomes were OS (analysed in the intention-to-treat population) and adverse events (analysed in all patients who received treatment and submitted adverse event information

2017 Lancet PubMed

113. Patient-reported tolerability of adverse events in phase 1 trials (Full text)

Patient-reported tolerability of adverse events in phase 1 trials Phase I experts recommend revisiting dose-limiting toxicity (DLT) definition to include chronic and cumulative toxicities induced by new molecularly targeted therapies. Patient's assessment of late toxicities' tolerability is, however, unknown.A prospective survey on adverse events (AEs) tolerability on 23 National Cancer InstituteCommon Terminology Criteria for Adverse Event, Version 4 (NCI-CTCAE.v4) items was conducted

2017 ESMO open PubMed

114. Response to - Adverse events associated with the use of cervical spine manipulation or mobilization and patient characteristics: A systematic review. (PubMed)

Response to - Adverse events associated with the use of cervical spine manipulation or mobilization and patient characteristics: A systematic review. 28583771 2018 06 06 2018 12 02 2468-7812 30 2017 08 Musculoskeletal science & practice Musculoskelet Sci Pract Response to - Adverse events associated with the use of cervical spine manipulation or mobilization and patient characteristics: A systematic review. e95 S2468-7812(17)30093-0 10.1016/j.msksp.2017.05.008 Kranenburg H A HA Research Group

2017 Musculoskeletal science & practice

115. Beta-blocker subtype and risks of perioperative adverse events following non-cardiac surgery: a nationwide cohort study (Full text)

Beta-blocker subtype and risks of perioperative adverse events following non-cardiac surgery: a nationwide cohort study Beta-blockers vary in pharmacodynamics and pharmacokinetic properties. It is unknown whether specific types are associated with increased perioperative risks. We evaluated perioperative risks associated with beta-blocker subtypes, overall and in patient subgroups.We performed a Danish Nationwide cohort study, 2005-2011, of patients treated chronically with beta blocker (...) (atenolol, bisoprolol, carvedilol, metoprolol, propranolol, or other) prior to non-cardiac surgery. Risks of 30-day all-cause mortality (ACM) and 30-day major adverse cardiovascular events (MACE) were estimated using adjusted logistic regression models and odds ratios with 95% confidence intervals. We identified 61 660 patients, most frequently treated with metoprolol (67% of patients, mean age 69 years, 49% males), atenolol (10% of patients, mean age 68 years, 36% males), or carvedilol (9% of patients

2017 EvidenceUpdates PubMed

116. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study)

Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study) We sought to develop a multiple biomarker approach for prediction of incident major adverse cardiac events (MACE; composite of cardiovascular death, myocardial infarction, and stroke) in patients referred for coronary angiography. In a 649-participant training

2017 EvidenceUpdates

117. Predictive factors for reporting adverse events following spinal manipulation in randomized clinical trials - secondary analysis of a systematic review. (Full text)

Predictive factors for reporting adverse events following spinal manipulation in randomized clinical trials - secondary analysis of a systematic review. While spinal manipulative therapy (SMT) is recommended for the treatment of spinal disorders, concerns exist about adverse events associated with the intervention. Adequate reporting of adverse events in clinical trials would allow for more accurate estimations of incidence statistics through meta-analysis. However, it is not currently known (...) if there are factors influencing adverse events reporting following SMT in randomized clinical trials (RCTs). Thus our objective was to investigate predictive factors for the reporting of adverse events in published RCTs involving SMT. The Physiotherapy Evidence Database (PEDro) and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for RCTs involving SMT. Domains of interest included: sample size; publication date relative to the 2010 CONSORT statement; risk of bias; the region treated

2017 Musculoskeletal science & practice PubMed

118. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. (Full text)

Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. Objectives To assess self reported outcomes and adverse events after self sourced medical abortion through online telemedicine.Design Population based study.Setting Republic of Ireland and Northern Ireland, where abortion is unavailable through the formal healthcare system except in a few restricted circumstances.Population 1000 (...) women who underwent self sourced medical abortion through Women on Web (WoW), an online telemedicine service, between 1 January 2010 and 31 December 2012.Main outcome measures Successful medical abortion: the proportion of women who reported ending their pregnancy without surgical intervention. Rates of adverse events: the proportion who reported treatment for adverse events, including receipt of antibiotics and blood transfusion, and deaths reported by family members, friends, or the authorities

2017 BMJ PubMed

119. Association between antipsychotics and cardiovascular adverse events: A systematic review. (Full text)

Association between antipsychotics and cardiovascular adverse events: A systematic review. Determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents.Analysis of original articles retrieved from the following databases: LILACS, PubMed, Cochrane Controlled Trials Clinical Data Bank (CENTRAL) and PsycINFO, without language restriction, dated until November 2015. After screening of 2,812 studies, three cohort original articles (...) , although the articles demonstrate an association between cardiovascular adverse events and the use of antipsychotics. More quality clinical trials are needed to support this evidence.

2017 Revista da Associacao Medica Brasileira (1992) PubMed

120. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p (Full text)

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials.In the Lipid (...) and should help counter the adverse effect on public health of exaggerated claims about statin-related side-effects.Pfizer, Servier Research Group, and Leo Laboratories.Copyright © 2017 Elsevier Ltd. All rights reserved.

2017 Lancet PubMed